Current Good Manufacturing Practice

Jump to

Mylan gets warning letter from USFDA for lapses at 3 units

The US regulator said its inspectors found "significant violations" in the three manufacturing facilities in Bengaluru of the company, which is an arm of US-based Mylan Inc
Cadila to see marginal impact of USFDA warning letter

Chirag Talati, pharma analyst at Espirito Santo Securities tells CNBC-TV18 that since the company does not generate any sales from the facility, and approval of the 18 ANDAs (Abbreviated New Drug Application) were not expected until FY13, FY12 margins will remain intact.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347

Current Good Manufacturing Practice

Mylan gets warning letter from USFDA for lapses at 3 units

Cadila to see marginal impact of USFDA warning letter